European Companies Search Engine

EU funding (€15.5M): Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies Hor 1 Jan 2020 EU Research and Innovation programme "Horizon"

Overview

Text

Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies

Immune-mediated diseases (IMIDs) are an increasing medical burden in industrialized countries worldwide. IMIDs are characterized by an enormous heterogeneity with regard to disease outcome and response to targeted therapies, which currently cannot be adequately anticipated to tailor individual patient management. Hence, mechanistic understanding of this heterogeneity and biomarkers predictive for disease control and therapy response over time are important prerequisites of a future precision medicine in IMIDs. ImmUniverse has been formed as a European transdisciplinary consortium to tackle these unmet needs and to understand the role of the crosstalk between tissue microenvironment and immune cells in disease progression and response to therapy of two different IMIDs: ulcerative colitis and atopic dermatitis. Following this unique cross-disease approach ImmUniverse will fill the gap and the limitations of current studies, which do not systematically compare the complex interactions between recirculating immune cells and the respective tissue microenvironment. The consortium will combine analysis of tissue-derived signatures with “circulating signatures” detectable in liquid biopsies, employing state-of-the-art profiling technologies corresponding to multi-Omics datasets. The project will also bring diagnostics in IMID to a new level by implementing disruptive non-invasive liquid-biopsy methodology in combination with novel, validated circulating biomarker assays which are expected to improve diagnosis, inform early in the clinical course on disease severity and progression and enable treatment response monitoring. The identified signature will be validated to monitor state/progression and response to therapy in prospective observational cohorts. Realization of these objectives will result in improvement of patient management, lead to increased patient well-being and will significantly reduce the socioeconomic burden of these diseases.


Funded Companies:

Company name Funding amount
Aarhus Universitet €174,488
Aarhus Universitetshospital €353,596
AIT Austrian Institute OF Technology GmbH €2,131,236
Centre Hospitalier Regional Universitaire Nancy €103,784
Christian-Albrechts-Universitaet ZU Kiel €2,915,000
Eli Lilly and Company Ltd. €0.00
Erasmus Universitair Medisch Centrum Rotterdam €105,000
Eurice European Research AND Project Office GmbH €704,063
European Federation OF Asthma &Allergy Associations Ideell Forening €50,250
Forum des Patients Europeens €11,781.25
Glaxosmithkline Research & Development Ltd. €0.00
Humanitas Mirasole S.p.A. €0.00
Information Technology FOR Translational Medicine (Ittm) SA €400,501
International Federation OF Crohn'S AND Ulcerative Colitis Associations €50,313
Istituto Superiore Di Sanita €502,989
Joanneum Research Forschungsgesellschaft mbH €894,909
Katholieke Universiteit Leuven €516,693
Ludwig-Maximilians-Universitaet Muenchen €392,975
Novartis Pharma AG €0.00
Pfizer Ltd. €0.00
Sanofi-Aventis Deutschland GmbH €0.00
Scuola Superiore Di Studi Universitari E Di Perfezionamento S Anna €360,000
Stichting Amsterdam UMC €633,048
Stichting Radboud Universitair Medisch Centrum €1,096,421
Stichting Radboud Universiteit €0.00
The Chancellor Masters and Scholars of the University of Cambridge €445,294
Universitaet ULM €210,000
Universita Humanitas €1,925,508
Universita Vita-Salute SAN Raffaele €96,313
Universite Du Luxembourg €780,939
VIB VZW €644,900

Source: https://cordis.europa.eu/project/id/853995

The filing refers to a past date, and does not necessarily reflect the current state.